+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Serum Prolactin Levels in Rats with Pituitary Transplants or Hypothalamic Lesions

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Serum prolactin levels were determined by radioimmunoassay in hypophysectomized, ovariectomized rats bearing 0, 1, 2, or 4 anterior pituitaries (AP) underneath the kidney capsule at 1, 2, 4, 6, 8, and 10 weeks after transplantation. Rats with no AP transplants had barely detectable levels of serum prolactin, whereas rats with 1 AP transplant from female cycling rats had serum prolactin values as high as those seen in estrous rats (120 ng/ml serum). In rats bearing 2 AP transplants, serum prolactin increased to 170 ng/ml serum, whereas 4 AP transplants elevated serum prolactin to 250 ng/ml, which is about equivalent to that in lactating postpartum rats (280 ng/ml). Injections of estradiol benzoate (1 µg/day for 5 days) into rats bearing 0, 1, 2, or 4 AP transplants, beginning 10 weeks after transplantation, increased serum prolactin over pre-treatment levels, except in the rats with no pituitary transplants. Bilateral lesions placed in the median eminence or anterior hypothalamus of ovariectomized rats significantly increased serum prolactin to 125 and 85 ng/ml, respectively, as compared with sham-lesioned controls (20 ng/ml). Posterior hypothalamic lesions increased serum prolactin concentration slightly and lesions in the amygdaloid nuclei had no effect. These results indicate that removal of hypothalamic inhibition of prolactin release by pituitary transplantation or by appropriate lesion placement in the hypothalamus results in elevated serum prolactin levels.

          Related collections

          Author and article information

          S. Karger AG
          19 March 2008
          : 6
          : 4
          : 220-227
          Department of Physiology, Michigan State University, East Lansing, Michigan, USA
          121946 Neuroendocrinology 1970;6:220–227
          © 1970 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 8


          Comment on this article